Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases

doi:10.1177/17588359241253127

科研成果详情

题名	Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases
作者	Hao, Yue 2,3; Xu, Manyi 2,3; Zeng, Xiaohong 4; Wang, Yina 5; Wang, Wenxian 6; Lin, Gen 7; Li, Bihui 8; Huang, Jianhui 9; Xu, Chunwei 10; Zhang, Yongchang 11; Song, Zhengbo 1
发表日期	2024
发表期刊	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	efficacy immunotherapy liver metastases thymic carcinoma
其他关键词	SINGLE-ARM ; PHASE-II ; MULTICENTER ; CANCER ; THYMOMA ; THERAPY
摘要	Background: Although immune checkpoint inhibitor treatment for advanced thymic carcinoma exhibits promising efficacy, factors that affect the efficacy and prognosis, including metastases sites, remain uncertain. Objectives: Our study aimed to investigate the determinants of survival among patients with advanced thymic carcinoma who underwent immunotherapy in real-world settings, with implications for clinical practice. Designs: Different therapy regimens of immunotherapy were produced to analyze the influence of liver metastases on survival and prognosis for advanced thymic carcinoma patients. Methods: Data for advanced thymic carcinoma patients receiving immunotherapy and their metastases sites were collected for analysis from seven different hospitals between January 2015 and January 2023. Progression-free survival (PFS) and overall survival (OS) analyses were performed using the Kaplan-Meier method. Cox analysis was used to evaluate factors influencing survival. Results: The present study analyzed 136 advanced thymic carcinoma patients from seven different hospitals. The PFS for all patients receiving immunotherapy was 6.4 months, while the OS was 24.0 months. The objective response rate was different for patients with liver and non-liver metastases (11.9% versus 37.2%, p = 0.003). The disease control rate values were also different between the two groups (47.6% versus 80.9%, p = 0.037). The PFS for patients with liver metastases demonstrated poor immunotherapy efficacy compared to patients with non-liver metastases (3.0 versus 8.0 months, p < 0.0001). The OS was also significantly different between these two patient groups (16.1 versus 29.1 months, p = 0.009). Results: The present study analyzed 136 advanced thymic carcinoma patients from seven different hospitals. The PFS for all patients receiving immunotherapy was 6.4 months, while the OS was 24.0 months. The objective response rate was different for patients with liver and non-liver metastases (11.9% versus 37.2%, p = 0.003). The disease control rate values were also different between the two groups (47.6% versus 80.9%, p = 0.037). The PFS for patients with liver metastases demonstrated poor immunotherapy efficacy compared to patients with non-liver metastases (3.0 versus 8.0 months, p < 0.0001). The OS was also significantly different between these two patient groups (16.1 versus 29.1 months, p = 0.009). Conclusion: Immunotherapy had poor efficacy in advanced thymic carcinoma patients with liver metastases.
资助项目	Foundation of CSCO-Shiyao [Y-SY201901-0068]; Zhejiang provincial program for the Cultivation of High-level Innovative Health talents
出版者	SAGE PUBLICATIONS LTD
ISSN	1758-8340
EISSN	1758-8359
卷号	16
DOI	10.1177/17588359241253127
页数	13
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:001234620800001
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	3881299
通讯作者地址	[Song, Zhengbo]Zhejiang Canc Hosp, Dept Clin Trial, 1 East Banshan Rd, Gongshu, Hangzhou 310022, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/214592
专题	温州医科大学
通讯作者	Song, Zhengbo
作者单位	1.Zhejiang Canc Hosp, Dept Clin Trial, 1 East Banshan Rd, Gongshu, Hangzhou 310022, Peoples R China; 2.Zhejiang Canc Hosp, Dept Clin Trial, Hangzhou, Peoples R China; 3.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China; 4.Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou, Peoples R China; 5.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Oncol, Hangzhou, Peoples R China; 6.Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China; 7.Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Canc Hosp, Fuzhou, Peoples R China; 8.Guilin Med Univ, Dept Oncol, Affiliated Hosp 2, Guilin, Peoples R China; 9.Lishui Municipal Cent Hosp, Dept Oncol, Lishui, Peoples R China; 10.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China; 11.Cent South Univ, Lung Canc & Gastrointestinal Unit, Affiliated Canc Hosp, Dept Med Oncol,Hunan Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China
推荐引用方式 GB/T 7714	Hao, Yue,Xu, Manyi,Zeng, Xiaohong,et al. Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY,2024,16.
APA	Hao, Yue., Xu, Manyi., Zeng, Xiaohong., Wang, Yina., Wang, Wenxian., ... & Song, Zhengbo. (2024). Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 16.
MLA	Hao, Yue,et al."Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases".THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 16(2024).